Frontlight ResearchEarly access
CompletedPhase 3
Early Oseltamivir Carboxylate Low Plasma Concentration in Patients Admitted to Intensive Care for Severe Influenza.
Key facts
- Who runs it
- Assistance Publique Hopitaux De Paris
- Where
- France23 sites in 1 countryChoose a country to see its sites
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 155 people enrolled
- Started
- 18 Dec 2023
- Ended
- 12 Oct 2026
- Type of study
- Interventional
- Record updated
- 3 February 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Patients over 18 years of age
- Confirmed severe influenza infection requiring intensive care with tracheal intubation for invasive mechanical ventilation (influenza ARDS with or without bacterial co-infection, cardiorespiratory decompensation of influenza origin, influenza myocarditis)
- Oseltamivir treatment administered through a gastric tube initiated since less than 24 hours (i.e. maximum two doses administered)
- Affiliation to a social security scheme, beneficiary or beneficiary entitled (excluding AME)
- Patient or, by default, a trusted support person or, by default, an informed family member who has given written consent or patient who has been included in emergency procedures
Who cannot take part
- Previous treatment with Zanamivir or other antiviral treatment active against influenza virus for more than 24 hours
- Administration of medication via nasogastric tube impossible
- Current participation in a therapeutic interventional trial or be in the exclusion period at the end of a clinical trial (drugs that may interact with paracetamol or oseltamivir)
- Co-infection with another respiratory virus (including SARS CoV-2)
- Pregnant or breastfeeding woman
- Patient deprived of liberty or under legal protection (guardianship or curatorship)
- For patients not included in emergency situations: Inability, according to the investigator, to understand or refusal to sign the informed consent to participate in the study (non-French-speaking patient)
- Weight less than 40 kg
- Patient benefiting from AME (Aide Médicale d'Etat)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To determine the prognostic impact of early plasma underdosing (measured at 48 hours of treatment) of oseltamivir carboxylate (OC) on early morbidity and mortality in patients hospitalized in the ICU for severe influenza infection.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- OPTIFLU. Prognostic Impact of Early Oseltamivir Carboxylate Low Plasma Concentration in Critically Ill Patients With Severe Influenza: a Prospective Cohort Study
- Record updated
- 3 February 2026